N-Hexoxypentyl-1-deoxynojirimycin

ID: ALA1651630

Chembl Id: CHEMBL1651630

PubChem CID: 53321623

Max Phase: Preclinical

Molecular Formula: C17H35NO5

Molecular Weight: 333.47

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCCCCCOCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO

Standard InChI:  InChI=1S/C17H35NO5/c1-2-3-4-7-10-23-11-8-5-6-9-18-12-15(20)17(22)16(21)14(18)13-19/h14-17,19-22H,2-13H2,1H3/t14-,15+,16-,17-/m1/s1

Standard InChI Key:  RCXJPSZNTHETPE-YYIAUSFCSA-N

Alternative Forms

1. Parent:

   

   ALA1651630

   N-Hexoxypentyl-1-deoxynojirimycin

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 333.47

Molecular Weight (Monoisotopic): 333.2515

AlogP: 0.51

#Rotatable Bonds: 12

Polar Surface Area: 93.39

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.90

CX Basic pKa: 8.23

CX LogP: 0.69

CX LogD: -0.21

Aromatic Rings: ┄

Heavy Atoms: 23

QED Weighted: 0.39

Np Likeness Score: 0.78

References

1. Ghisaidoobe A, Bikker P, de Bruijn AC, Godschalk FD, Rogaar E, Guijt MC, Hagens P, Halma JM, Van't Hart SM, Luitjens SB, van Rixel VH, Wijzenbroek M, Zweegers T, Donker-Koopman WE, Strijland A, Boot R, van der Marel G, Overkleeft HS, Aerts JM, van den Berg RJ..  (2011)  Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.,  2  (2): [PMID:24900289] [10.1021/ml100192b]

2. De Fenza M, D'Alonzo D, Esposito A, Munari S, Loberto N, Santangelo A, Lampronti I, Tamanini A, Rossi A, Ranucci S, De Fino I, Bragonzi A, Aureli M, Bassi R, Tironi M, Lippi G, Gambari R, Cabrini G, Palumbo G, Dechecchi MC, Guaragna A..  (2019)  Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.,  175  [PMID:31075609] [10.1016/j.ejmech.2019.04.061]

Source

Source(1):

• Scientific Literature